Want to create an interactive transcript for this episode?
Podcast: CME
Episode: What’s New About Gout? Rheumatology Perspective
Description:
Host: Richard Johnson, MD
Guest: John K. Botson, MD, RPh
This activity is no longer available for continuing education credit. Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.